Giorgos Aristotelous

What was studied?This case–control observational study investigated the associations between peripheral blood cytokine profiles and gut microbiota composition in patients with Graves’ disease (D), the most common autoimmune thyroid disorder. The study aimed to elucidate the interplay between immune dysregulation—specifically changes in cytokines such as interleukin-10 (L-10), transforming growth factor β (GF-β), and interleukin-17A (L-17A)—and […]

This study reveals distinct compositional changes in the gut microbiota of Graves’ disease patients, notably increased Bacteroidetes and Prevotellaceae and decreased Firmicutes and Lachnospiraceae, suggesting potential microbial biomarkers and a role for gut dysbiosis in the disease’s pathogenesis.

This study reveals distinct gut microbiome alterations in Graves’ disease, identifies 12 key bacterial genera as diagnostic signatures, and shows microbiota recovery after antithyroid therapy, linking dysbiosis to immune regulation and disease pathogenesis.

This prospective study identifies a unique gut microbiome signature in Graves’ disease, characterized by decreased CFA-producing bacteria and increased pro-inflammatory taxa, which partially recovers with antithyroid therapy. Twelve genera robustly distinguish D, offering potential for early diagnosis and microbiome-targeted interventions.

Integrated microbiome-metabolome study reveals dysbiosis and metabolic shifts in Graves’ disease and hypothyroidism, highlighting potential biomarkers like depleted Bacteroides for thyroid disorders.

This study demonstrates that Graves’ disease and Hashimoto’s thyroiditis patients share distinct gut microbiome signatures—particularly involving Bacillus, Blautia, and Ornithinimicrobium—and a common enrichment of the BC transporter pathway, supporting a microbiome-driven mechanism in autoimmune thyroid disease pathogenesis.

This study identified distinct alterations in gut microbiota composition and function in Graves’ disease and Graves’ orbitopathy patients compared to healthy controls, highlighting specific microbial taxa and metabolic pathways that may contribute to disease mechanisms and serve as future biomarkers.

This cross-sectional study found that Graves’ disease patients have distinctly altered gut microbiota—lower Firmicutes, higher Bacteroidetes, and reduced butyrate-producers—suggesting a role for the microbiome in disease pathogenesis and as a diagnostic biomarker.

This study reveals that Graves’ disease is linked to distinct gut microbiota alterations, particularly increased Ruminococcus and Lactobacillus and decreased Synergistetes and Phascolarctobacterium, which correlate with thyroid autoantibody status and may serve as microbiome-based biomarkers for disease activity and therapeutic response.

Graves’ disease patients show distinctive gut microbiota profiles, with increased Bacteroidetes and specific pro-inflammatory bacteria, despite no difference in overall diversity. Key taxa correlate with clinical D parameters, highlighting their potential as diagnostic biomarkers and supporting a role for gut dysbiosis in D pathogenesis.